www.tickerreport.com ·
oncolytics biotech nasdaqoncy announces earnings results misses estimates by 0 03 eps
Topic context
This topic has been covered 247644 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEarnings miss for a clinical-stage biotech firm; no product revenue, no supply chain or commodity impact. The miss is small ($0.03) and does not change the fundamental commercial outlook for the sector. No concrete commercial mechanism beyond the company's own cash burn and pipeline progress.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Oncolytics Biotech reported Q1 2026 EPS loss of $0.08, missing consensus estimate of -$0.05 by $0.03.
- Stock price $0.87, market cap $101.37M, 52-week range $0.33-$1.51.
- Consensus rating 'Moderate Buy' with average price target $8.50.
- Institutional ownership 6.82%.
Oncolytics Biotech's Q1 earnings miss may lead to a minor negative sentiment for small-cap biotech stocks within 48h; PHARMA_BIOTECH is affected down.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort
